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DR52 and -DR7) and HLA-DQ (-DQ2) for one donor. 
Finally we demonstrated that purified peptide-induced 
CD4+ from one donor could inhibit the growth of EBV- 
infected autologous B-cells in the early phase of trans- 
formation. 
Conclusion: This EBNA2 synthetic peptide is very 
promising to design an EBV vaccine for nonimmune 
individuals awaiting solid organ transplantation. 
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Background: Virus-virus interactions may influence 
the pathogenesis of defined human viral infections. 
Using the clinical setting of liver transplantation (LT), 
we investigated the potential role that P-herpesviruses 
may play in the course of HCV infection. 
Methods: In 93 consecutive HCV-infected patients 
followed for a mean of 32 months post-LT, the incidence 
of CMV, human herpesvirus (HHV) -6 and -7 replication 
(assessed by PCR on 6 weekly serum samples) and CMV 
disease were evaluated for their impact on HCV- 
induced cirrhosis, retransplantation or mortality (primary 
end point). HCV replication and recurrence of HCV- 
induced hepatitis and fibrosis (assessed at 16 and 
52 weeks post-LT) were evaluated as secondary end 
points. Statistical analysis was performed using fre- 
quency tables, Kaplan Meier estimation, and proportional 
hazards regression. 
Results: The primary end point developed in 28% of 
patients. Independent of other significant predictors, we 
observed that CMV (40/91 [35.2%]) but not HHV-6 and 
-7 reactivation, and CMV disease (23/93 [24.7%]) were 
associated with the primary end point (Risk Ratio [RR], 
1.003; 95% CI, 1.001-1.004; P=O.O02; and RR, 4.189; 
95% CI, 1.838-9.546; P=O.OOl, respectively). Early CMV 
reactivation was strongly associated with mortality 
(8/32 [25%] vs O/59 [O%]; P<O.OOl). CMV disease was 
also associated with higher fibrosis stage (mean ( SD, 
1.0?1.19 vs 0.49 (0.83;P=O.O4), modified hepatitis activity 
index (mean+-SD, 4.17k3.07 vs 2.96k2.42; P=O.O9), 
and plasma HCV RNA level (mean?SD, 55.71250.47 
vEq/ml vs 36.17k46.95 vEq/ml; P=O.O7) at 16 weeks 
post-LT. 
Conclusion: Using the human model of LT, our study 
demonstrates that the pathogenesis of HCV is strongly 
and independently influenced by its interaction with 
CMV but not HHV-6 and -7. The lack of association 
between HCV and the other P-herpesviruses implies 
that the impact of CMV on HCV may be mediated by a 
direct HCV-CMV interaction that is beyond immuno- 
modulation, Importantly, it is observed that even low 
level CMV replication that does not evolve into clinical 
disease influences HCV outcome. Thus, aggressive CMV 
prevention may positively influence the clinical outcome 
of HCV-infected LT patients. 
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Background: XLP is an inherited immunodeficiency 
caused by SAP mutations. XLP often manifests itself 
as fulminant or fatal infectious mononucleosis after 
primary EBV infection; however, EBV is apparently 
unrelated to development of lymphoma or dysgamma- 
globulinemia, other major manifestations of XLP Thus, 
how this virus involves the pathogenesis of XLP remains 
obscure. We experienced a patient with XLP who did not 
acquire any serious condition after primary EBV 
infection but eventually developed virus-associated 
hemophagocytic syndrome (VAHS) and malignant lym- 
phoma (ML) upon reactivation of EBV. 
Case Report: A 12-year-old boy presented with a 16-day 
history of fever and lumbago. Both the patient and his 9 
year old brother have been known to have hypogamma- 
globulinemia of unknown etiology, and were seropositive 
to EBV with uneventful past medical histories, except 
for several episodes of otitis media and an episode of 
pneumonia in the patient. Abdominal CT revealed para- 
aortic and pelvic lymphadenopathy. Open biopsy of the 
lymph nodes was performed, which showed necrotic 
tissue with no malignant cells. He did not respond anti- 
biotics, and subsequently VAHS was diagnosed. Despite 
intensive therapy including plasma exchange, immuno- 
suppressants and VP16, he deteriorated with develop- 
ment of multiple novel nodular lesions in lungs and 
bilateral pleural effusions, and died from multiple organ 
failure. Cytological analysis of pleural fluid was com- 
patible to malignant transformation. 
Immunologic Studies: Intracellular staining of SAP 
protein showed decreased SAP expression in T cells 
derived from these brothers. Direct sequencing revealed 
missense mutation S34G in their SAP genes. Plasma 
EBV load in the patient, determined by real-time PCR, 
was undetectable on admission, but markedly increased 
to 2.2~10~ copies/ml when he developed VAHS. In 
striking contrast, EBV-specific CTL was barely detect- 
able by MHC-peptide tetramer method. 
Conclusions: Despite impaired EBV-specific immunity, 
primary EBV infection in the patient, and also in his 
brother, appeared insignificant. Nevertheless, he ulti- 
mately developed such serious EBV-associated diseases 
as VAHS and ML. Thus, role of EBV infection in the 
pathogenesis of XLP may be complex. 
